Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

74.73USD
24 Apr 2019
Change (% chg)

-- (--)
Prev Close
$74.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,922,945
52-wk High
$83.81
52-wk Low
$56.26

Latest Key Developments (Source: Significant Developments)

Applied Lifesciences & Systems Closes $8 Mln Equity Round
Friday, 22 Mar 2019 04:50pm EDT 

March 22 (Reuters) - Applied Lifesciences & Systems::APPLIED LIFESCIENCES & SYSTEMS ANNOUNCES CLOSING OF ITS $8 MILLION SERIES A ROUND OF EQUITY FINANCING.APPLIED LIFESCIENCES & SYSTEMS SAYS CLOSED $8 MILLION ROUND OF EQUITY FINANCING, CO-LED BY MERCK ANIMAL HEALTH AND MOUNTAIN GROUP PARTNERS.  Full Article

EMA Adopts Positive Opinion For Merck's Keytruda For 6-Week Dosing Schedule
Monday, 4 Mar 2019 06:45am EST 

March 4 (Reuters) - Merck & Co Inc ::EUROPEAN MEDICINES AGENCY ADOPTS POSITIVE OPINION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) FOR SIX-WEEK DOSING SCHEDULE ACROSS ALL CURRENT MONOTHERAPY INDICATIONS.MERCK & CO INC - FINAL DECISION ON MARKETING AUTHORIZATION IS EXPECTED IN Q2 OF 2019..  Full Article

Us FDA Approves Ontruzant, Samsung Bioepis' First Oncology Medicine In The U.S.
Sunday, 20 Jan 2019 06:38pm EST 

Jan 20 (Reuters) - Samsung Bioepis Co: :US FDA APPROVES ONTRUZANT® (TRASTUZUMAB-DTTB), SAMSUNG BIOEPIS’ FIRST ONCOLOGY MEDICINE IN THE UNITED STATES.SAMSUNG BIOEPIS CO - ONTRUZANT WILL BE MARKETED AND DISTRIBUTED IN UNITED STATES BY MERCK, WHICH IS KNOWN AS MSD OUTSIDE OF US AND CANADA.  Full Article

Moderna Announces Recent Progress In Its Immuno-Oncology And Rare Disease Programs And Highlights Corporate Objectives
Tuesday, 8 Jan 2019 08:30am EST 

Jan 8 (Reuters) - Moderna Inc ::MODERNA ANNOUNCES RECENT PROGRESS IN ITS IMMUNO-ONCOLOGY AND RARE DISEASE PROGRAMS AND HIGHLIGHTS CORPORATE OBJECTIVES.MODERNA INC - IND AMENDMENT SUBMITTED TO FDA FOR A PHASE 2 COHORT OF OX40L (MRNA-2416) TO TREAT ADVANCED OVARIAN CARCINOMA.MODERNA INC - PLANNING FOR A PHASE 2 STUDY OF PERSONALIZED CANCER VACCINE (MRNA-4157) INITIATED TOGETHER WITH STRATEGIC COLLABORATOR MERCK.MODERNA INC - EXPECT OUR CASH, CASH EQUIVALENTS, AND INVESTMENTS IN MARKETABLE SECURITIES AS OF DECEMBER 31, 2018 TO BE ABOUT $1.7 BILLION.  Full Article

Amunix Announces Licensing Agreement With Merck For Protia Immune Activator Platform
Thursday, 3 Jan 2019 03:29pm EST 

Jan 3 (Reuters) - Amunix Pharmaceuticals::AMUNIX ANNOUNCES LICENSING AGREEMENT WITH MERCK FOR PROTIA IMMUNE ACTIVATOR PLATFORM.AMUNIX PHARMACEUTICALS - FINANCIAL DETAILS OF AGREEMENT WERE NOT DISCLOSED.AMUNIX PHARMACEUTICALS - UNDER TERMS OF AGREEMENT, AMUNIX WILL RECEIVE AN UPFRONT PAYMENT FROM MERCK.  Full Article

Cocrystal Pharma Announces Collaboration Agreement With Merck
Thursday, 3 Jan 2019 08:30am EST 

Jan 3 (Reuters) - Cocrystal Pharma Inc ::COCRYSTAL PHARMA ANNOUNCES EXCLUSIVE WORLDWIDE LICENSE AND COLLABORATION AGREEMENT WITH MERCK.COCRYSTAL PHARMA INC - COCRYSTAL WILL BE PAID AN UNDISCLOSED UPFRONT SUM.COCRYSTAL PHARMA INC - MERCK TO FUND RESEARCH AND DEVELOPMENT FOR PROGRAM.COCRYSTAL PHARMA INC - MERCK WILL BE RESPONSIBLE FOR WORLDWIDE COMMERCIALIZATION OF ANY PRODUCTS DERIVED FROM COLLABORATION.COCRYSTAL PHARMA - ELIGIBLE TO RECEIVE PAYMENTS RELATED TO DESIGNATED DEVELOPMENT, REGULATORY & SALES MILESTONES WITH POTENTIAL TO EARN UP TO $156 MILLION.  Full Article

Personal Genome Diagnostics collaborates with Merck on global clinical trial evaluating response to dual biomarker directed precision oncology combination therapy
Thursday, 3 Jan 2019 08:00am EST 

Jan 3 (Reuters) - Merck & Co Inc ::PERSONAL GENOME DIAGNOSTICS COLLABORATES WITH MERCK ON GLOBAL CLINICAL TRIAL EVALUATING RESPONSE TO DUAL BIOMARKER DIRECTED PRECISION ONCOLOGY COMBINATION THERAPY.PERSONAL GENOME DIAGNOSTICS-REPORTED ITS 500+ GENE PAN-CANCER TUMOR PROFILING TISSUE ASSAY BEING USED IN MERCK'S PHASE 2 PRECISION ONCOLOGY KEYIMPACT STUDY.  Full Article

Ra Pharmaceuticals Receives Development Milestone Payment Under Agreement With Merck
Thursday, 6 Dec 2018 07:30am EST 

Dec 6 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS RECEIVES DEVELOPMENT MILESTONE PAYMENT UNDER AGREEMENT WITH MERCK.RA PHARMACEUTICALS INC - RECEIVED A DEVELOPMENT MILESTONE PAYMENT UNDER ITS COLLABORATION AGREEMENT WITH MERCK, KNOWN AS MSD OUTSIDE US AND CANADA.RA PHARMACEUTICALS INC - CO ELIGIBLE TO EARN UP TO $59 MILLION IN ADDITIONAL MILESTONE PAYMENTS FROM MERCK.RA PHARMACEUTICALS - ALSO ELIGIBLE TO RECEIVE LOW-TO-MID SINGLE DIGIT PERCENTAGE ROYALTIES ON FUTURE SALES OF COMPOUNDS RESULTING FROM COLLABORATION.  Full Article

NewLink Genetics Says Merck Has Begun Rolling Submission Of Licensure Application For Ebola Vaccine V920
Thursday, 15 Nov 2018 09:03am EST 

Nov 15 (Reuters) - NewLink Genetics Corp ::NEWLINK GENETICS ANNOUNCES MERCK HAS BEGUN ROLLING SUBMISSION OF LICENSURE APPLICATION FOR EBOLA VACCINE V920 (RVSV∆G-ZEBOV-GP) TO U.S. FOOD AND DRUG ADMINISTRATION.NEWLINK GENETICS - ROLLING SUBMISSION IS MADE PURSUANT TO FDA'S BREAKTHROUGH THERAPY DESIGNATION FOR V920.  Full Article

Merck Begins Rolling Submission Of Licensure Application For V920 To U.S. FDA
Tuesday, 13 Nov 2018 04:35pm EST 

Nov 13 (Reuters) - Merck & Co Inc ::MERCK BEGINS ROLLING SUBMISSION OF LICENSURE APPLICATION FOR V920 (RVSV∆G-ZEBOV-GP) TO U.S. FOOD AND DRUG ADMINISTRATION.MERCK & CO INC - CURRENTLY, MERCK EXPECTS ROLLING SUBMISSION OF BLA TO BE COMPLETED IN 2019.  Full Article

Photo

Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.